Chimeric Therapeutics (ASX:CHM)
ASX announcement history & article coverage
Transparent by design.
Announcments by Chimeric Therapeutics (ASX:CHM) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Application for quotation of securities - CHM
Appendix 4E and Preliminary Final Report
Application for quotation of securities - CHM
Application for quotation of securities - CHM
CHM ceases enrolment in Phase 1 trial and Company update
Trading Halt
Application for quotation of securities - CHM
Quarterly Activities/Appendix 4C Cash Flow Report
Chimeric Therapeutics reports positive clinical progress, capital consolidation, and strategic review with $0.8M cash at June 2026
Chimeric receives $1.62M advance on FY26 R&D tax incentive
Chimeric Therapeutics secures $1.62M advance on FY26 R&D tax incentive to fund clinical trials
Investor Presentation
Application for quotation of securities - CHM
Notification regarding unquoted securities - CHM
Notification regarding unquoted securities - CHM
CHM CDH17 Phase 1 clinical trial update - New DL 3 data
Chimeric Therapeutics reports promising interim Phase 1 data for CHM CDH17 CAR-T therapy with tumor shrinkage and stable disease
Application for quotation of securities - CHM
Notification of cessation of securities - CHM
Final Director's Interest Notice
Board Update
Application for quotation of securities - CHM
Appointment of Financial Adviser for Strategic Review
Chimeric Therapeutics appoints independent adviser for strategic review to maximize shareholder value
Application for quotation of securities - CHM